FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions

Device center reviewers will begin applying the guidance to incoming PMA and de novo submissions and to submissions already under review with decisions beginning on May 1.

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation